screening for a predisposition to cancer 11-12
screening window 11-7
for genetic disease
newborn screening 10-11
screening for adult-onset disease 10-12
threshold likelihood ratio for acceptance 10-11
threshold likelihood ratio for followup 10-11
for subclinical disorders
components 5-1
probability of detecting a disorder 5-1
threshold likelihood ratio for acceptance 3-13
threshold likelihood ratio for followup 3-13
Selection bias
in evaluation of classification studies 4-4
Sensitivity
definition 3-1
variability 3-3
Sex
pregnancy 6-5
sex-based variability 6-4
SI units
conversion to common units 1-4
definition 1-2
table of 1-3
table of magnitude prefixes 1-4
Southern blot hybridization
molecular diagnosis 10-5
Specificity
definition 3-1
variability 3-3
Stimulation study
in the evaluation of endocrine function 7-9
Study population
in evaluation of classification studies 4-3
Suppression study
in the evaluation of endocrine function 7-9
Synthetic rate
as determinant of substance plasma concentration 7-1
organ synthetic rate 7-2
T U
Test panels
of injury markers 9-4
Test-review bias
in evaluation of classification studies 4-5
Therapeutic drug monitoring
definition 12-12
dosing adjustment 12-14
plasma concentration target 12-12
steady state 12-13
therapeutic range 12-13
Tissue injury
see
Injury
TNM staging system
in cancer prognosis 11-15
Trace minerals
circulating forms 8-3
deficiency 8-5
storage form 8-3
supply reserve 8-3
table of 8-1
Transfusion
ABO blood group 9-10
compatibility testing 9-10
markers of post-transfusion hemolysis 9-12
monitoring post-transfusion 9-12
Rh blood group 9-10
Transplantation
histocompatibility testing 9-9
HLA antigens 9-8
markers of transplant rejection 9-10
monitoring post-transplant 9-10
transfusion 9-10
V
Validation study
in evaluation of classification studies 4-8
Variability
age-based variability 6-6
analytic variability
definition 1-6
sources of 1-6
biorhythms 6-8
biologic variability
components of 1-5, 6-1
continuous heterogeneity 6-3
definition 1-5
discrete heterogeneity 6-1
sources of 1-5, 6-1
laboratory error 1-6
method imprecision
components 2-5
definition 2-5
evaluation 2-20
pharmacologic 12-5
preanalytic variability
definition 1-5
sources of 1-5
postanalytic variability
definition 1-6
sources of 1-6
race-based variability 6-5
sex-based variability 6-4
study performance 3-3
sources 1-5
V(D)J rearrangement in cancer 11-5
Vitamins
circulating forms 8-3
deficiency 8-5
storage form 8-3
supply reserve 8-3
Index
9
